NCT03632668View on ClinicalTrials.gov

Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

January 24, 2019

Study Completion Date

January 24, 2019

Conditions
HyperlipidemiasHypertension
Interventions
DRUG

AD-2071 10/20mg

AD-2071 10/20 mg tablet

DRUG

AD-2072 80/5mg

AD-2072 80/5mg tablet

DRUG

AD-2071 10/20mg + AD2072 80/5mg

AD-2071 10/20 mg + AD-2072 80/5mg tablet

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT03632668 - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 | Biotech Hunter | Biotech Hunter